Article | January 18, 2022

Testing Cell Line Development Technology Platforms In Parallel

By Dr. Sufia Karim and Dr. Steven Lang, Aragen Bioscience, Inc

GettyImages-164198023-cell-line-development

How confident are you in your ability to reach appropriate titers for an unknown biologic?

This question is at the heart of decision-making when choosing a cell line development (CLD) platform. When pharmaceutical sponsors have the ability to do so, testing multiple platforms to determine which will produce optimal titers provides process insight and mitigates risk. However, platform testing requires sponsors and their partners to balance timelines against the amount of parallel work, arriving at a data-supported resolution as quickly as possible.

In many cases, vendors overpromise and underdeliver. A sponsor’s only recourse — most of the time — is to find a forthcoming and knowledgeable vendor that can provide insight into why a given timeline may be unrealistic, a budget may be miscalculated, or a cost of goods sold (COGS) may be overly optimistic.

This article reviews the CLD platform options, multiple platform testing, and next steps.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: